We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
JAMA Patient Page |

Treatment Duration for Pulmonary Embolism FREE

Jill Jin, MD, MPH
JAMA. 2015;314(1):98. doi:10.1001/jama.2015.7431.
Text Size: A A A
Published online

The type and duration of treatment for pulmonary embolism can vary from person to person.


Pulmonary embolism (PE) is the presence of a blood clot (embolus) that blocks an artery in the lungs. Usually the clot comes from a piece of another blood clot inside a vein of the legs (deep vein thrombosis [DVT]) that has broken off and traveled to the lungs. Pulmonary emboli can range from very small and causing no symptoms to very large and causing symptoms of shortness of breath, chest pain, and dizziness. Some large pulmonary emboli can be fatal.


Blood-thinning medication is the main treatment for PE. How long to thin the blood depends on where the clot that went to the lung came from and why it formed.

Deciding how long treatment should last requires carefully weighing the risks and benefits of thinning blood for each individual person. Taking a blood thinner for too short a time can result in a clot returning after treatment is stopped. Taking a blood thinner for too long can increase the risk of bleeding as a side effect. The ideal duration of treatment depends on the individual’s risk of having another blood clot compared with the individual’s risk of bleeding, which the doctor takes into account. Currently, the recommended treatment duration ranges from a minimum of 3 months to a maximum of lifelong treatment.

A study published in the July 7, 2015, issue of JAMA addressed this question. This study was a randomized clinical trial involving more than 350 people who had a first-ever PE that was unprovoked. Unprovoked PE means there was no clear risk factor such as recent travel, surgery, or trauma to cause the clot. Having unprovoked PE means there is a higher risk of having another blood clot in the future compared with clots caused by a reversible, temporary risk factor (such as a long airplane ride).

The study compared the effects of giving blood-thinning medication for 6 months compared with 2 years. The study looked at how often people in each group had (1) another blood clot and (2) major bleeding as a side effect. The results showed a significantly lower risk of having another blood clot in the group that received the treatment for longer (2 years), without a major increase in bleeding risk.

If you have had a first-time PE without a clear cause, you may benefit from longer treatment with blood thinners than the usual 3 to 6 months. Talk to your doctor about your individual risks and benefits for taking blood thinners vs having another blood clot.

Box Section Ref ID

For More Information

To find this and previous JAMA Patient Pages, go to the Patient Page link on JAMA’s website at jama.com. Many are available in English and Spanish. A Patient Page describing how blood thinners work was published in the December 18, 2013, issue; one on DVT was published in the May 26, 2015, issue; and one on PE was published in the February 6, 2013, issue.


The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 312/464-0776.

Source: Couturaud F, Sanchez O, Pernod G, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial. JAMA. doi:10.1001/jama.2015.7046.

Topic: Drug Therapy



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Spanish Patient Page: Duración del tratamiento para la embolia pulmonar

Supplemental Content

Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...